Urology Articles

Eligibility for bladder-preservation in high-grade bladder cancer depends on patient and tumor characteristics. This article covers methods for assessing eligibility and explores treatment options when first-line BCG therapy fails.

BCG failure can be classified as BCG-refractory, relapsing, and intolerant disease. Learn about BCG failure in high-risk non-muscle invasive bladder cancer, and treatment strategies after BCG failure.

With guidance from urologic oncologists Dr. James Eastham and Dr. Aditya Bagrodia, this article covers how to effectively involve prostate cancer biochemical recurrence patients in diagnostic and treatment decisions.

Urologist Dr. Spencer Hiller provides a detailed review of the HoLEP procedure, detailing equipment selection and procedure steps.

HoLEP is increasingly recognized as a valuable surgical treatment for BPH. However, incontinence and leakage are common HoLEP side effects, necessitating a focused post-operative protocol. Learn how to minimize HoLEP side effects with expert guidance from Dr. Spencer Hiller.

Biochemical recurrence in prostate cancer—defined by a rising PSA after definitive treatment—poses challenges in surveillance and treatment decision-making. Learn more about risk assessment before and after prostatectomy, PSA monitoring thresholds, imaging advancements, and considerations for adjuvant and salvage therapies.

Dr. David Albala explains his algorithm for stratifying prostate cancer risk and how it informs treatment, focusing on the role of new biomarkers, imaging methods, and biopsy techniques.

Prostate cancer screening has evolved from blanket PSA testing to a nuanced, precision-focused approach that integrates genomic insights, biomarkers, and advanced imaging techniques. Dr. David Albala explains the role of tools such as ExosomeDx and SelectMDx biomarkers, MRI fusion biopsies, and personalized risk assessments to refine screening practices.